This is a federal contract award from the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health (NIH), to the La Jolla Institute for Immunology (LJII), a non-profit research institute. The contract, valued at $52,963,056.00, is for the "IMMUNE EPITOPE DATABASE AND ANALYSIS PROGRAM" and does not have a set-aside designation. The contract is a definitive contract with a cost-no-fee pricing type, with a period of performance ending on...
The National Institute of Allergy and Infectious Diseases (NIAID), a civilian agency, awarded a $5,624,889.00 definitive contract to the La Jolla Institute For Immunology, a non-profit research institute. The contract is for the identification and validation of epitopes conserved in viral pathogen families with pandemic potential. This is a cost-no-fee contract with a period of performance through September 29, 2025. The contract has no set-aside designation. The La Jolla Institute For...
This is a federal contract award from the National Institute of Allergy and Infectious Diseases (NIAID), a component of the National Institutes of Health (NIH), to the La Jolla Institute for Immunology, a non-profit research institute. The $5,982,815.17 definitive contract is for biomedical research services, with a period of performance from September 30, 2009 to September 29, 2014. The contract did not have a set-aside designation. The La Jolla Institute for Immunology, which conducts...
This is a definitive federal contract awarded by the National Institute of Allergy and Infectious Diseases (NIAID), a component of the U.S. Department of Health and Human Services, to the La Jolla Institute for Immunology, a non-profit research institute. The contract, valued at $5,624,672.00, is for the identification and characterization of T cell epitopes from bacterial pathogens causing pneumonia. This research aims to advance the understanding of immune responses to these bacterial...
This is a federal contract award (HHSN272200700048C) from the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health (NIH), to the La Jolla Institute for Immunology, a non-profit research institute. The $6,415,863 definitive contract is for biomedical research services, with a period of performance from September 2007 to December 2014. The contract does not have a set-aside designation. The La Jolla Institute for Immunology specializes in...
This definitive federal contract was awarded by the Department of Health and Human Services' National Institute of Allergy and Infectious Diseases to the La Jolla Institute for Immunology, a non-profit research organization, to conduct large-scale T cell epitope discovery research. The contract has a potential value of $4,499,760.00 and is not set aside for any specific business type. The contract involves multiple subcontractors to assist with the research, including the Universidad Peruana...
This is a $162,950,791.20 cost-plus-fixed-fee definitive contract awarded by the National Institute of Allergy and Infectious Diseases (NIAID), a civilian federal agency, to Leidos, Inc. Research And Development Division. The contract is for biomedical (basic) research and development services, and does not have a set-aside designation. The contract is associated with larger contract vehicles, including the One Acquisition Solution for Integrated Services (OASIS) and Alliant II Governmentwide...
This federal contract award for $1,049,692.00 was issued by the Centers for Disease Control and Prevention (CDC) to the La Jolla Institute for Immunology, a non-profit research institute. The contract, which does not have a set-aside designation, supports a "Systemic Assessment of Immunity to B. Pertussis Using Validated Assays & Data Integration" under Broad Agency Announcement (BAA) Topic 22.3. The contract is a definitive contract with a cost-no-fee pricing type and an...
This is a federal contract award valued at $69,299,577.00 issued by the National Institute of Allergy and Infectious Diseases (NIAID), a part of the National Institutes of Health (NIH), to the prime contractor Leidos Biomedical Research Inc. The contract is for the NIAID DCR OPERATIONAL TASK ORDER and has an ultimate completion date of August 30, 2025. It is a cost-plus-fixed-fee delivery order contract. The contract does not have a set-aside designation. Leidos Biomedical Research Inc. is a...
This federal contract award, with an ID of HHSN261201500003I|HHSN26100020, was issued by the National Institute of Allergy and Infectious Diseases (NIAID), a civilian agency within the U.S. government. The $2,010,201.84 contract was awarded to Leidos Biomedical Research Inc., a subsidiary of Leidos Holdings, Inc., on September 1, 2016, with a performance period ending on September 30, 2019. The contract is a Delivery Order, with a Cost No Fee pricing type. It does not have a set-aside...
This is a $36,549,202.01 definitive contract awarded by the National Institute of Allergy and Infectious Diseases (NIAID) to the La Jolla Institute for Immunology, a non-profit research institute, for the Immune Epitope and Analysis Program. The contract has no set-aside designation and is set to run until December 14, 2025.
As the prime contractor, the La Jolla Institute for Immunology is responsible for the overall program, which involves conducting research and providing services related to infectious diseases, allergies, autoimmune disorders, cancer, and vaccine development. The institute has engaged two major subcontractors to support the effort:
Danmarks Tekniske Universitet (DTU), also known as the Technical University of Denmark, which is tasked with maintaining, enhancing, and developing new epitope prediction tools for the Immune Epitope Database and Analysis Resource (IEDB).
Leidos, Inc., operating through its Leidos Services Operating Segment Division, which is responsible for maintaining and improving the existing IEDB database and curation systems.
This contract aligns with NIAID's broader mission to conduct and support research to better understand, treat, and prevent infectious, immunologic, and allergic diseases.